Anti-IL-17A mAb treatment during this period of infection reduced immune cell infiltration at early stages of infection (2 and 4 weeks postinfection) (S8C Fig) and reduced lung fibrosis, bacterial burden and mortality at chronic stages of infection (after 39 weeks of infection). Here, IL17A is linked to fibrosis.